Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 12/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17073105 | 0.94 | HMGCR (0.46) | HMGCR | |
| SCHEMBL19524874 | 0.94 | HMGCR (0.46) | HMGCR | |
| SCHEMBL28432429 | 0.94 | HMGCR (0.46) | HMGCR | |
| SCHEMBL4453080 | 0.91 | HMGCR (0.48) | HMGCR | |
| SCHEMBL4451033 | 0.91 | HMGCR (0.48) | HMGCR | |
| SCHEMBL8511795 | 0.91 | HMGCR (0.46) | HMGCR | |
| SCHEMBL1347123 | 0.91 | HMGCR (0.49) | HMGCR | |
| SCHEMBL2034579 | 0.90 | HMGCR (0.46) | HMGCR | |
| SCHEMBL2050591 | 0.90 | HMGCR (0.46) | HMGCR | |
| SCHEMBL20699721 | 0.90 | HMGCR (0.48) | HMGCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2373609-B1 | USE OF AMPHIPHILIC COMPOUNDS FOR CONTROLLED CRYSTALLIZATION OF STATINS AND STATIN INTERMEDIATES | KRKA D D NOVO MESTO (SI) | 2013-10-16 | — | — | EP | claimed |
| EP-2327682-A1 | Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates | KRKA, D.D., Novo Mesto (SI) | 2011-06-01 | — | — | EP | claimed |
| WO-2019008593-A1 | PROCESS FOR MANUFACTURE OF ROSUVASTATIN CALCIUM AMORPHOUS | Melody Healthcare Pvt. Ltd (IN) | 2019-01-10 | — | — | WO | disclosed |
| US-8034932-B2 | Hydroxy-3-methylglutaryl/3-/ coenzyme A reductase inhibitor; anticholesterol agents;dyslipidemia; chemical intermediate for rosuvastatin | ASTRAZENECA UK LIMITED (GB) | 2011-10-11 | — | — | US | disclosed |
| EP-2361906-A1 | Process for preparing rosuvastatin | AstraZeneca UK Limited (GB) | 2011-08-31 | — | — | EP | disclosed |
| US-20080207903-A1 | Chemical Process | ASTRAZENECA UK LIMITED (GB) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207903-A1 | Chemical Process | CYP2C9, CYP2B6, CYP7A1 | HMGCR 306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.